Purchase Order 75N95024P00536
Award Date
9/23/24
Potential Completion Date
11/18/24
Potential Value
$24K
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Pharmaron, Inc.
Ultimate Awardee
Not listed
NAICS Category
541380 - Testing Laboratories and Services
PSC Category
B504 - Special Studies/Analysis- Chemical/Biological
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
China
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. for $24,624.00. The contract is to obtain pharmacokinetic exposure data from mouse PK studies and plasma protein binding assays, which are common preclinical services provided by Pharmaron, a global contract research organization (CRO) specializing in drug discovery and development. This contract...
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Pharmaron, Inc.'s Phamaron Inc. Division. The contract, valued at $23,040.00, is for a pharmacokinetics assessment of eight novel compounds in mice and rats. Pharmaron is a global contract research organization (CRO) that specializes in preclinical research services, including pharmacokinetics assessments, toxicity...
This firm fixed-price purchase order contract, valued at $54,000.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a division of the National Institutes of Health (NIH), to Pharmaron, Inc. Pharmaron is a minority-owned, for-profit Subcontinent Asian (Asian-Indian) American contract research organization that specializes in preclinical drug discovery and development services. The contract is for testing 20 small molecule compounds in rat pharmacokinetic...
The Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences awarded a $108,000 purchase order to Pharmaron, Inc. for pharmacokinetics experiments involving forty rodents across two study arms. The one-year contract has Pharmaron performing the work in China under a firm fixed price arrangement. No additional details were provided on subcontractors or the specific NIH programs the research aims to support. The award information...
This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...
This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) to Pharmaron, Inc. for $75,600 to conduct ion channel block, IC50 determination testing on 60 compounds over a period of 12 months. The work supports drug discovery and development efforts for the National Center for Advancing Translational Sciences (NCATS) and involves evaluating compounds for potential cardiotoxicity. The contract does not have a set-aside designation. Pharmaron is a global contract...
This firm fixed-price purchase order was awarded by the Department of Health and Human Services' (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct testing of compounds for the blocking of cardiac ion channels. The period of performance is from August 7, 2020 to December 31, 2021, with a potential value of $24,795.00. The work is being performed in Louisville, Kentucky....
This firm fixed-price purchase order, valued at $78,300.00, was awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency, to Pharmaron, Inc., a minority-owned, for-profit organization classified as a Subcontinent Asian (Asian-Indian) American owned business. The contract is for the testing of compounds to block cardiac ion channels, with a period of performance ending on November 16, 2022. Pharmaron, a global contract research organization (CRO) specializing...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) awarded a firm fixed price purchase order contract valued at $10,440.00 to Pharmaron, Inc., a minority-owned, for-profit organization based in China. The contract is for a pharmacokinetic study of the drugs tamoxifen and neurotinib, with a period of performance running through October 9, 2023. Pharmaron has received over 30 prior prime contract awards...
This federal contract award to Pharmaron, Inc., a Minority Owned Business and For Profit Organization, was issued by the U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS). The contract, valued at $117,930.00, is a Firm Fixed Price Purchase Order to evaluate NNMT inhibitors in metabolic disorders. Pharmaron, a global contract research organization, will conduct various drug development activities...